A meta-analysis of four observational studies (n = 5590 patients) revealed that anthracycline-treated individuals receiving SGLT2 inhibitors experienced a significantly lower risk of all-cause mortality (RR = 0.55, 95% CI: 0.39–0.77), while heart failure incidence showed a non-significant downward trend (RR = 0.67, 95% CI: 0.40–1.41) [156]. This evidence concerns the gene SLC5A2 and heart failure.